LEGN vs ZLAB: How Legend Biotech and Zai Lab Limited Compare (2026)

Same yardstick, side by side (as of August 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. LEGN and ZLAB share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined LEGN and ZLAB exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

Legend Biotech is a global cell-therapy company best known for CARVYKTI (ciltacabtagene autoleucel, or cilta-cel), a one-time BCMA-directed CAR-T treatment for relapsed or refractory multiple myeloma. It develops and commercializes CARVYKTI in a 50/50 profit-and-cost-sharing collaboration with Johnson & Johnson, so Legend's reported revenue shows up largely as collaboration and license income rather than direct product sales. The company also runs an earlier-stage pipeline of other cell therapies and solid-tumor programs, but CARVYKTI drives essentially all of the current commercial narrative.

Full LEGN guide

Zai Lab was built on a specific arbitrage: find drugs that already work, license the Greater China rights before or during late-stage development, run the local trials and regulatory process, and sell them through a domestic commercial organization that Western partners do not want to build. That produced a portfolio of marketed products including ZEJULA (niraparib, a PARP inhibitor for ovarian cancer), the VYVGART franchise (efgartigimod, partnered with argenx, for generalized myasthenia gravis), XACDURO (sulbactam-durlobactam for Acinetobacter infections) and NUZYRA (omadacycline), with newer approvals for AUGTYRO, TIVDAK and KarXT rolling into launch through 2026. Total revenue was about $460 million in 2025 and roughly $450 million over the trailing twelve months, and management has described the China commercial business as profitable on its own before corporate R&D.

Full ZLAB guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• LEGN drivers: CARVYKTI commercial ramp; Move to earlier lines of therapy.
• ZLAB drivers: Zoci as the first globally owned asset; Newly approved products entering commercial ramp.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: Legend's value is heavily concentrated in one product, CARVYKTI, and in one partner, Johnson & Johnson, which shares profits and controls much of the commercial engine. For ZLAB, zai Lab's revenue is concentrated in mainland China and is therefore exposed to administered pricing rather than market pricing: national reimbursement drug list renewals cut prices as a condition of volume, and volume-based procurement of generics can collapse a branded franchise quickly, which is what happened to ZEJULA when generic olaparib entered.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick LEGN if you believe its drivers more; ZLAB if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the LEGN and ZLAB guides.

LEGN. LEGN trades as a high-multiple growth biotech whose revenue is recognized mainly as collaboration and license income under the J&J profit split, distinct from CARVYKTI's roughly $1.9 billion in 2025 global net trade sales. The company is approaching adjusted breakeven while still reporting losses, so the valuation reflects expectations for continued CARVYKTI growth rather than current earnings. Wall Street price targets vary widely, underscoring how much hinges on the pace of the ramp.

ZLAB. There is no earnings multiple to quote because Zai Lab does not earn anything yet, so the stock is valued on revenue, cash and pipeline probability instead. Backing out roughly $717 million of cash leaves about $1.6 billion of enterprise value against $450 million of trailing revenue, which is a low multiple for a specialty pharma commercial base and implies the market assigns close to nothing for the wholly owned oncology pipeline. Bulls point at that gap, bears point at a revenue line that shrank year over year in both Q1 and Q2 2026 while operating expenses stayed above $130 million a quarter.

Headline figures (approximate, JULY 2026): LEGN shows revenue (ttm, collaboration/license) ~$1.1B, carvykti net trade sales (fy2025, global) ~$1.9B, q1 2026 total revenue ~$305M, fy2025 adjusted net loss ~$33M; ZLAB shows revenue (ttm) ~$450 million, up ~5% year over year, q2 2026 revenue ~$106.3 million, down ~3% year over year but up ~11% sequentially on product sales, net loss ~$50.8 million in Q2 2026, ~$188 million over the trailing twelve months, cash and investments ~$717.5 million as of June 30, 2026.

LEGN and ZLAB are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined LEGN and ZLAB exposure against your real portfolio. It is not an investment adviser.